Abbott Laboratories Q3 FY2026 results
$108.52+1.18%
Abbott Laboratories reported revenue of $13.0 billion, up 14.5% from a year earlier, net income of $920 million and diluted earnings per share of $0.53 against $0.94 for the third quarter of fiscal 2026 (the three months to 30 Sep 2026).
From its quarterly report, filed 4 Nov 2026. Compiled and checked by AapWire.
Q3 FY2026 against Q3 FY2025
Three months to 30 Sep 2026, against the three months to 30 Sep 2025. Amounts in USD.
| Measure | Q3 FY2026 | Q3 FY2025 | Change |
|---|---|---|---|
| Revenue | $13.01B | $11.37B | +14.5% |
| Gross profit | $7.38B | $6.29B | +17.3% |
| Gross margin | 56.8% | 55.4% | +1.4 pts |
| Operating income | $1.36B | $2.06B | −34.0% |
| Operating margin | 10.4% | 18.1% | −7.7 pts |
| Net income | $920.0M | $1.64B | −44.0% |
| Diluted EPS | $0.53 | $0.94 | −43.6% |
| Operating cash flow | $1.74B | $2.79B | −37.7% |
| Capital expenditure | $513.0M | $496.0M | +3.4% |
| Free cash flow | $1.22B | $2.29B | −46.6% |
Operating KPIs for the quarter
| KPI | Q3 FY2026 | Change on a year |
|---|---|---|
| Diabetes Care revenue | $2.2B | up 6.2% |
| Core Laboratory revenue | $1.4B | up 5.4% |
| Adult Nutritionals revenue | $1.2B | up 2.0% |
| Key Emerging Markets revenue | $1.2B | up 8.9% |
| Pediatric Nutritionals revenue | $1.1B | up 8.8% |
| Cancer Diagnostics revenue | $968.0M | — |
| Rapid and Molecular revenue | $899.0M | up 1.1% |
| Electrophysiology revenue | $873.0M | up 14.9% |
| Vascular revenue | $786.0M | up 5.5% |
| Rhythm Management revenue | $752.0M | up 9.6% |
| Structural Heart revenue | $592.0M | up 2.1% |
| Heart Failure revenue | $387.0M | up 5.7% |
| Neuromodulation revenue | $251.0M | down 1.2% |
| Medical Devices revenue | $5.8B | up 6.9% |
| Diagnostic Products revenue | $3.3B | up 46.7% |
| Nutritional Products revenue | $2.3B | up 5.1% |
| Established Pharmaceuticals revenue | $1.6B | up 6.8% |
Earlier quarters
| Quarter | Period end | Revenue | Change on a year | Diluted EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $13.01B | +14.5% | $0.53 |
| Q2 FY2026 | 30 Jun 2026 | $12.59B | +13.0% | $0.53 |
| Q1 FY2026 | 31 Mar 2026 | $11.16B | +7.8% | $0.61 |
| Q4 FY2025 | 31 Dec 2025 | $11.46B | +4.4% | $1.03 |
| Q3 FY2025 | 30 Sep 2025 | $11.37B | +6.9% | $0.94 |
| Q2 FY2025 | 30 Jun 2025 | $11.14B | +7.4% | $1.01 |
| Q1 FY2025 | 31 Mar 2025 | $10.36B | +4.0% | $0.76 |
| Q4 FY2024 | 31 Dec 2024 | $10.97B | +7.2% | $5.28 |
More on Abbott Laboratories: financial statements · revenue · earnings per share
ABT's results, as they are filed.
Releases read within minutes, guidance against results, the quarter in its eight-quarter history, and an alert on each new report.
